{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:22Z","timestamp":1793136982347,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.amjcard.2025.01.032","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T13:10:44Z","timestamp":1738329044000},"page":"68-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Real-World Assessment of Mavacamten's Impact on Left Ventricular Systolic and Diastolic Functions in Obstructive Hypertrophic Cardiomyopathy: A 1-Year Single-Center Observational Study"],"prefix":"10.1016","volume":"242","author":[{"given":"Zaid","family":"Abood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Fuad","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muddasir","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhjot","family":"Hundal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Misicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Ghafoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Jahangir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-1275","authenticated-orcid":false,"given":"A. Jamil","family":"Tajik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2025.01.032_bib0001","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0002","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0003","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/ehjci\/jex215","article-title":"Marked respiratory-related fluctuations in left ventricular outflow tract gradients in hypertrophic obstructive cardiomyopathy: an observational study","volume":"19","author":"Jain","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0004","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0033-0620(68)90011-X","article-title":"Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis","volume":"11","author":"Cohen","year":"1968","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0006","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.amjcard.2022.12.008","article-title":"Regional disparities in the use of septal reduction therapy and associated outcomes in the United States (from a real-world database)","volume":"191","author":"Ashraf","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0008","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacbts.2019.06.004","article-title":"Electrophysiological and contractile effects of disopyramide in patients with obstructive hypertrophic cardiomyopathy: a translational study","volume":"4","author":"Coppini","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0010","doi-asserted-by":"crossref","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten decreases maximal force and Ca(2+) sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy","volume":"320","author":"Awinda","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0011","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030607","article-title":"Long-term safety and efficacy of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: interim results of the PIONEER-OLE Study","volume":"13","author":"Masri","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0014","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0015","unstructured":"Bristol Myers Squibb. Full prescribing information (CAMZYOS). Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214998s000lbl.pdf. Accessed April 2, 2024."},{"key":"10.1016\/j.amjcard.2025.01.032_bib0016","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0017","article-title":"Mavacamten safety and dfficacy in a heart transplant patient exhibiting obstructive hypertrophic cardiomyopathy phenotype","volume":"29","author":"Abood","year":"2024","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0018","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0019","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ehf2.14882","article-title":"Mavacamten in real-life practice: initial experience at a hypertrophic cardiomyopathy centre","volume":"12","author":"Abood","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0021","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pcad.2024.02.001","article-title":"Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center","volume":"86","author":"Desai","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1429230","article-title":"One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy","volume":"11","author":"Kim","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0023","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pcad.2024.05.008","article-title":"Predictors of short-term and long-term effects of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"86","author":"Roehl","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.amjcard.2025.01.032_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011188","article-title":"Long-term effects of mavacamten on electromechanical dispersion and deformation in obstructive hypertrophic cardiomyopathy","volume":"17","author":"Del Franco","year":"2024","journal-title":"Circ Heart Fail"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:08:29Z","timestamp":1762078109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":24,"alternative-id":["S0002914925000566"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.01.032","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Assessment of Mavacamten's Impact on Left Ventricular Systolic and Diastolic Functions in Obstructive Hypertrophic Cardiomyopathy: A 1-Year Single-Center Observational Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}